Clinical Trials

Neoplasm Metastasis

NCT03907475 2026-04-13

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

115 enrolled

Phase 2 Active not recruiting

Neoplasm Metastasis

NCT05554341 2026-04-13

Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial

40 enrolled

Neoplasm Metastasis

NCT05554380 2026-04-13

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial

Phase 2 Suspended

33 enrolled

Phase 3 Active not recruiting

Neoplasm Metastasis

NCT05112965 2026-04-06

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

49 enrolled

Neoplasms

NCT02379416 2026-04-01

Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors

47 enrolled

Neoplasms

NCT04449549 2026-03-27

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

82 enrolled

Neoplasms

NCT01374620 2026-03-16

PAL-ANGI2

28 enrolled

Neoplasms

NCT03976362 2026-02-25

KEYLYNK-008

Phase 3 Completed

851 enrolled 25 charts

Carcinoma

NCT05365581 2026-02-13

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Phase 1 Recruiting

398 enrolled

Phase 3 Active not recruiting

Adenocarcinoma

NCT03768063 2026-01-29

IMbrella B

1,000 enrolled

Neoplasms

NCT05283226 2026-01-23

Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy

21 enrolled

Phase 2 Not yet recruiting

Carcinoma

NCT07346196 2026-01-20

A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck

90 enrolled

Carcinoma, Squamous Cell

NCT06320405 2025-12-29

Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors

Phase 1/2 Recruiting

38 enrolled

Phase 2 Active not recruiting

Neoplasm Metastasis

NCT00781612 2025-12-24

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

720 enrolled

Neoplasm Metastasis

NCT03498521 2025-11-19

CUPISCO

529 enrolled 16 charts

Neoplasms, Unknown Primary

NCT05977998 2025-11-19

A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology

30 enrolled

Carcinoma

NCT06246110 2025-11-12

A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

70 enrolled

Neoplasm Metastasis

NCT03564691 2025-10-07

MK-4830-001

470 enrolled

Neoplasms

NCT05407675 2025-10-03

A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors

Phase 1/2 Completed

68 enrolled 27 charts

Phase 3 Active not recruiting

Neoplasms

NCT04879368 2025-07-17

INTEGRATEIIb

450 enrolled

Adenocarcinoma, Carcinoma, Neoplasm Metastasis

NCT03918278 2025-06-25

MK-0482-001

222 enrolled

Phase 2 Not yet recruiting

Neoplasms

NCT06904300 2025-06-05

Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G/GEJ Cancer

110 enrolled

Neoplasms

NCT03719924 2025-01-08

OESIRI

106 enrolled

Carcinoma, Squamous Cell

NCT02723955 2024-12-27

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

829 enrolled 100 charts

Neoplasms

NCT02794571 2024-12-05

Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

518 enrolled

Neoplasm Metastasis

NCT03873883 2024-09-19

IO-001

119 enrolled

Neoplasms

NCT03292822 2024-06-20

Effects of (Licochalcone A) and Paclitaxel on Human Oral Squamous Cell Carcinoma Cell Line

18 enrolled

Carcinoma, Squamous Cell

NCT02483247 2023-11-14

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

165 enrolled

Neoplasms

NCT02317874 2023-08-29

Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer

43 enrolled

Neoplasm Metastasis

NCT00176267 2023-06-01

Paclitaxel, Carboplatin And Low Dose Radiation As Induction Therapy In Locally Advanced Head And Neck Cancer

26 enrolled

Carcinoma, Carcinoma, Squamous Cell

NCT00176254 2023-05-16

Paclitaxel, Carboplatin and Radiotherapy as Induction Therapy in Locally Advanced Head and Neck Cancer

40 enrolled 9 charts

Carcinoma, Carcinoma, Squamous Cell

NCT02761694 2023-05-06

MK-4440-001

Phase 1 Terminated

78 enrolled 28 charts

Neoplasms

NCT01015222 2022-11-23

Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies

122 enrolled

Neoplasm Metastasis

NCT03665441 2022-10-18

Trybeca-1

Phase 3 Completed

512 enrolled 19 charts

Neoplasms

NCT05552807 2022-09-23

SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1 Unknown

120 enrolled

Carcinoma, Squamous Cell

NCT05467189 2022-07-20

Antineoplastic Drugs in Elderly Patients

Recruiting

500 enrolled

Neoplasms

NCT02630199 2022-06-15

Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer

65 enrolled

Neoplasms

NCT05241132 2022-02-15

Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary

Phase 2 Unknown

27 enrolled

Neoplasms

NCT01362374 2022-01-12

Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors

122 enrolled

Neoplasms

NCT01968915 2020-12-19

Safety and Tolerability of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors

9 enrolled

Neoplasms

NCT01285466 2020-12-09

A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab

110 enrolled

Neoplasm Metastasis, Neoplasms

NCT01633970 2020-10-08

A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

240 enrolled

Neoplasms

NCT01653470 2020-01-28

Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors

141 enrolled

Neoplasms

NCT03057366 2019-11-18

A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors

8 enrolled 26 charts

Neoplasms

NCT00848718 2019-11-12

MK-2206-003

77 enrolled 24 charts

Neoplasms

NCT01868022 2019-08-19

Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling

65 enrolled 32 charts

Neoplasms

NCT01938846 2019-01-04

BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors

90 enrolled 22 charts

Neoplasms

NCT00954512 2018-08-24

Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)

Phase 1/2 Terminated

15 enrolled 11 charts

Neoplasms

NCT03636685 2018-08-17

Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC

Phase 1/2 Unknown

60 enrolled